|
|
Kaletra (Lopinavir/Ritonavir)
| Brand Name: |
Kaletra |
| Generic Name: |
Lopinavir/Ritonavir, LPV/RTV |
| Adult Single Dose*: |
Two tablets (400 mg/100 mg) twice daily or 4 tablets (800 mg/200 mg) once daily |
| Food & Liquid Restrictions: |
Take with or without food. Side effects may be lessened with food. |
| Drug Class: |
PI |
| * This recommendation is for patients starting HIV treatment. A different dose is recommended for treatment experienced patients. |
The Basics
- An Overview of Kaletra (Lopinavir/Ritonavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Lopinavir + Ritonavir (Kaletra) (August 22, 2009)
To read PDF, click here
From AIDS InfoNet
- Medication Guide for Kaletra (April 6, 2009)
Created by the makers of Kaletra specifically for people with HIV. Includes a rundown of possible side effects, reasons why Kaletra may not be a good fit for everybody, meds to avoid while taking Kaletra, and tips on how to maximize the chances Kaletra will work well.
From Abbott Laboratories
- Kaletra (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Patient Information About Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution (PDF) (April 2009)
From Abbott Laboratories
- Patient Frequently Asked Questions (November 2007)
Information about the new Kaletra (lopinavir/ritonavir) tablets.
From Abbott Laboratories
- Kaletra (Lopinavir/Ritonavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Patient Information About Kaletra (Lopinavir/Ritonavir) Capsules (PDF) (July 2007)
From Abbott Laboratories
- Lopinavir (Kaletra) (August 15, 2006)
From AIDS Treatment Data Network
- Kaletra (Lopinavir/Ritonavir) (November 2005)
[Archived Article]
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Kaletra (August 2004)
[Archived Article]
From Project Inform
- The Debate Over Kaletra (Lopinavir/Ritonavir) "Monotherapy" (August 2004)
[Archived Article]
From amfAR, The Foundation for AIDS Research
- What Role, Kaletra? (Spring 2001)
[Archived Article]
To read PDF, click here
In CRIA Update, from AIDS Community Research Initiative of America
- Drug Fact Sheet: Lopinavir/Ritonavir (Kaletra) (December 2000)
[Archived Article]
To read PDF, click here
In Research Initiative/Treatment Action!, from The Center for AIDS
- Kaletra (ABT-378/r) Approved (September 22, 2000)
[Archived Article]
Details and information sources on Kaletra (lopinavir plus low-dose ritonavir), a newly approved protease inhibitor approved last week.
In AIDS Treatment News, from AIDS Treatment News
- FDA Approves Kaletra for HIV Infection (September 15, 2000)
[Archived Article]
FDA issues accelerated approval for enhanced protease inhibitor.
From U.S. Food and Drug Administration
- Lopinavir: The Most Potent Protease Inhibitor (Summer 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
News
- FDA Warns Abbott on Magic Johnson DVD for HIV Drug (July 23, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Labeling Changes for Kaletra Reflecting New QT/QTC Interval and PR Interval Prolongation Information (April 7, 2009)
HIVers who have "electrical" problems with their heart -- problems that impact their heart rhythm, for instance -- should be wary of using Kaletra (lopinavir/ritonavir), according to new information added to the drug's official labeling.
From U.S. Food and Drug Administration
- WHO Approves Heat-Stable, Generic Version of Abbott's Kaletra (February 26, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abbott Drug Pricing Condemned by AIDS Advocates in International Protests (January 27, 2009)
In coordinated actions, protesters in Mexico, Colombia and the U.S. demand that Abbott lowers the price of its key AIDS drug Kaletra; advocates otherwise vow to seek compulsory licenses in Colombia and Mexico; in U.S., AHF to also premiere 60-second video parody blasting Abbott and CEO Miles White on YouTube and place spot as TV commercial on select Chicago-area television stations.
From AIDS Healthcare Foundation
- New Pediatric Dosing Information for Kaletra, Patients 14 Days to 6 Months and 12-18 Years of Age and Update Information on Coadministration With Midazolam (PDF) (June 23, 2008)
From U.S. Food and Drug Administration
- Newly-Unsealed Documents Shed Light on Abbott Labs' 400% Norvir Price Hike (May 12, 2008)
Union, consumer groups decry Abbott for putting profits before HIV/AIDS patients' needs
In A Closer Walk: A Film by Robert Bilheimer, from Community Catalyst
- Abbott Receives FDA Approval for Lower-Dose of Kaletra for Children (November 13, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Kaletra and Accidental Overdose in Children (PDF) (August 16, 2007)
Direct Healthcare Professional communication on Kaletra (lopinavir/ritonavir) solution and accidental overdose in children.
From Abbott Laboratories
- Abbott, FDA Warn About Possible Overdose of Antiretroviral Kaletra in Children (August 15, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Student Global AIDS Campaign Responds to Abbott's Decision to Reduce Price of Kaletra in Low and Middle Income Countries (April 10, 2007)
From Student Global AIDS Campaign
- The State of Access to Kaletra (April-July 2006)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- FDA Approval of New Formulation of Kaletra (October 28, 2005)
[Archived Article]
From U.S. Food and Drug Administration
- Brazil Nears New Deal With Abbott on Price of Kaletra (October 4, 2005)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Research
- Kaletra and Gemfibrozil (Lopid): A Match Not Made in Lipid Heaven (August 19, 2009)
Researchers have found that Lopid may not work as well in people who are taking the HIV medication Kaletra (lopinavir/ritonavir). But what does this finding actually mean for people with HIV?
From The Body
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Does Kaletra Monotherapy Work? Depends on Who You Ask (October 27, 2008)
Project Inform says the latest findings on Kaletra monotherapy are anything but positive.
From Project Inform
- Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. (February 14, 2008)
In Journal of Acquired Immune Deficiency Syndromes
- Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People (February 6, 2008)
From The Body PRO
- Lopinavir/Ritonavir Monotherapy or Plus Zidovudine and Lamivudine in Antiretroviral-Naive HIV-Infected Patients (January 30, 2008)
In AIDS
- EACS: Kaletra Monotherapy May Need Excellent Adherence to Work (October 31, 2007)
In aidsmap.com
- ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
- Kaletra-Based Regimens May Suppress Viral Load Despite Missed Doses (May 1, 2007)
In Journal of Acquired Immune Deficiency Syndromes
- Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Predictors of Virologic Rebound on Lopinavir/Ritonavir Monotherapy (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The GEMINI Study: Are Saquinavir + Ritonavir and Lopinavir/Ritonavir Twins? (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- Long-Term Lopinavir/Ritonavir Treatment and CD4+ Cell Responses (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
- Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain (August 17, 2006)
In XVI International AIDS Conference
- Treating Patients With Lopinavir/Ritonavir Alone Still Risky (August 17, 2006)
In XVI International AIDS Conference
- Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- During the Third Trimester of Pregnancy Lopinavir/Ritonavir Dose Should Be Increased, Study Finds (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- Better Adherence With Once-Daily Versus Twice-Daily Lopinavir/Ritonavir: New Tablet Formulation Has Improved GI Tolerability (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Brazil, Abbott Reach Deal to Lower Price on Antiretroviral Drug Kaletra (October 12, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Brazil Again Seeks Negotiations With Abbott to Lower Price on Antiretroviral Drug Kaletra (August 19, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Coming Soon: New Lopinavir/Ritonavir (Kaletra) Formulation Allowing for 2-Tablet, Twice-Daily Dosing (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Full Virologic Suppression Can Be Maintained With Lopinavir/Ritonavir Alone; Single-Agent Therapies Worth Further Investigation (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Once-Daily Lopinavir/Ritonavir Approved for Treatment-Naive Patients (April 29, 2005)
[Archived Article]
From U.S. Food and Drug Administration
- Notice of Important New Drug Interactions With Norvir, Kaletra (March 30, 2005)
[Archived Article]
New interactions noted with fluticasone (a component of Flonase nasal spray) and trazodone (Desyrel, an antidepressant).
From U.S. Food and Drug Administration
- Don't Combine Fosamprenavir and Lopinavir/Ritonavir (February/March 2005)
[Archived Article]
From The Body PRO
- Lopinavir/Ritonavir Monotherapy in Treatment-Naive Patients (January 2005)
[Archived Article]
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO
- Kaletra Monotherapy Controversy: amfAR Publishes Overview (October 26, 2004)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Summary of Kaletra (Lopinavir/Ritonavir) Labeling Revisions (October 22, 2004)
[Archived Article]
Long-term efficacy and safety results from two phase II trials have now been included.
From U.S. Food and Drug Administration
- Hepatitis Testing Important for HIVers Before Taking Kaletra (October 13, 2004)
[Archived Article]
From aidsmap.com
- Hepatitis/HIV Coinfection Linked to Liver Complications in Kaletra Patients (September 2004)
[Archived Article]
Abstract of a study that recommends testing HIV-infected patients for HBV and HCV and measuring their baseline ALT values before lopinavir/ritonavir therapy is begun.
In HIV Medicine
- Response to Lopinavir/Ritonavir in HIV-Infected Patients Coinfected With Hepatitis C and/or Hepatitis B (July 12, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Drug Development News: Abbott (May/June 2004)
[Archived Article]
New formulations of lopinavir/ritonavir (Kaletra) and ritonavir are in the works.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- First Case of Potential PI Cross-Resistance Reported After Lopinavir Failure (April 29, 2004)
[Archived Article]
From aidsmap.com
- Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
- Lexiva + Kaletra -- Still a Bad Idea (March/April 2004)
[Archived Article]
A short review of a study presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network
- Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nelfinavir, Lopinavir/Ritonavir Appear Safe for Hepatitis C Patients (February 10, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Boosted Atazanavir Similar to Boosted Lopinavir in Treatment-Experienced Patients (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Once-Daily Lopinavir/Ritonavir as Effective as Twice-Daily, but Greater Side Effects Are Concern (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Unboosted Atazanavir Better on Insulin Sensitivity Compared to Lopinavir/Ritonavir (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- HIV Drug Kaletra Proves Effective in Five-Year Study (September 16, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Kaletra "Monotherapy" Safe and Efficacious for Treatment-Naive Patients (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- 908 vs. Kaletra: Comparable for Experienced Patients, Not for Naive (July 28, 2003)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Kaletra: Could Upping the Dose Overcome Resistance? (July 18, 2003)
[Archived Article]
A 67 percent increase in the lopinavir/ritonavir dose was found to be far more effective than increasing only the ritonavir.
From aidsmap.com
- Research From the 42nd ICAAC: High Lopinavir Levels Predict High Lipids (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Decreased Plasma Concentrations of Amprenavir and Lopinavir in HIV Patients on This Combination (July 8, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Antiretroviral Update: Lopinavir/Ritonavir (Kaletra) (November 2001)
[Archived Article]
In HEPP News, from Brown Medical School
- Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Efficacy of Lopinavir in Heavily Pretreated Patients (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- A New Side Effect From Kaletra? (May 25, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- FDA Issues Pancreatitis Warning for New Drug Lopinavir (March 2001)
[Archived Article]
In WISE Words, from Project Inform
- Head-to-Head Study of Two Protease Inhibitors (March 2001)
[Archived Article]
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Kaletra: Abbott Joins the Bandwagon (Spring 2001)
[Archived Article]
Recap of Kaletra's Phase III trial results and expanded access program.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Lopinavir (Kaletra) Update: Study M97-765 (September 2000)
[Archived Article]
In Research Initiative/Treatment Action!, from The Center for AIDS
- Lopinavir/Ritonavir (Norvir) Plus Either Efavirenz (Sustiva) or Nevirapine (Viramune) and Two NRTIs (Autumn 2000)
[Archived Article]
Highlights from the XIII International AIDS Conference.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- New Drugs in Development (Fall 2000)
[Archived Article]
Lopinavir (Kaletra; ABT-378/r).
In CRIA Update, from AIDS Community Research Initiative of America
- Kaletra™ (ABT-378/r) Early Access Program Can Accept More Patients (August 18, 2000)
[Archived Article]
More patients can now receive this experimental protease inhibitor.
In AIDS Treatment News, from AIDS Treatment News
- ABT-378/Ritonavir and Efavirenz for Salvage Therapy in Patients Multiply-Exposed to PIs (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Kaletra™ (ABT-378/r) Application for Accelerated Approval (June 23, 2000)
[Archived Article]
Overview of new protease inhibitor moving toward wider use.
In AIDS Treatment News, from AIDS Treatment News
- Lopinavir: The Most Potent Protease Inhibitor (Summer 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Expanded Access Program for ABT-378/r Amended (May 2000)
[Archived Article]
In Positive Living, from AIDS Project Los Angeles
- Lopinavir Shows Good Activity (April 2000)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Selected Highlights From the 7th CROI: ABT-378 (Lopinavir) Plus Ritonavir, d4T, and 3TC (Spring 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Abbott Expands ABT-378/Ritonavir Early-Access Program (February 2000)
[Archived Article]
In Positive Living, from AIDS Project Los Angeles
- ABT-378 "Early Access" Program (December 1999)
[Archived Article]
In Body Positive, from Body Positive
- Treatment News: Expanded Access Program for ABT-378 Under Way (November 1999)
[Archived Article]
Triangle Pharma Coactinon combo may suppress HIV.
In Positive Living, from AIDS Project Los Angeles
- ABT-378 Early Access Program Begins (October 1, 1999)
[Archived Article]
From AIDS Treatment News
- ABT-378: Abbott "Second Generation" Protease Inhibitor (February 21, 1997)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- ABT-378: A New Protease Inhibitor From Abbott (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- More Data on Higher-Dose Lopinavir/Ritonavir (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
|
Advertisement
|
E-Mail
Glossary
Share